GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ambrx Biopharma Inc (NAS:AMAM) » Definitions » PS Ratio

Ambrx Biopharma (Ambrx Biopharma) PS Ratio : 69.78 (As of May. 25, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ambrx Biopharma PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Ambrx Biopharma's share price is $9.70. Ambrx Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.14. Hence, Ambrx Biopharma's PS Ratio for today is 69.78.

Warning Sign:

Ambrx Biopharma Inc stock PS Ratio (=1400) is close to 1-year high of 1400

The historical rank and industry rank for Ambrx Biopharma's PS Ratio or its related term are showing as below:

AMAM' s PS Ratio Range Over the Past 10 Years
Min: 421.5   Med: 713   Max: 1400
Current: 1400

During the past 4 years, Ambrx Biopharma's highest PS Ratio was 1400.00. The lowest was 421.50. And the median was 713.00.

AMAM's PS Ratio is not ranked
in the Biotechnology industry.
Industry Median: 9.18 vs AMAM: 1400.00

Ambrx Biopharma's Revenue per Sharefor the three months ended in Jun. 2023 was $0.02. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.14.

Warning Sign:

Ambrx Biopharma Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Ambrx Biopharma was -91.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was -47.70% per year.

During the past 4 years, Ambrx Biopharma's highest 3-Year average Revenue per Share Growth Rate was -47.70% per year. The lowest was -47.70% per year. And the median was -47.70% per year.

Back to Basics: PS Ratio


Ambrx Biopharma PS Ratio Historical Data

The historical data trend for Ambrx Biopharma's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ambrx Biopharma PS Ratio Chart

Ambrx Biopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22
PS Ratio
- - 24.81 11.82

Ambrx Biopharma Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
PS Ratio Get a 7-Day Free Trial - - - - -

Competitive Comparison of Ambrx Biopharma's PS Ratio

For the Biotechnology subindustry, Ambrx Biopharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ambrx Biopharma's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ambrx Biopharma's PS Ratio distribution charts can be found below:

* The bar in red indicates where Ambrx Biopharma's PS Ratio falls into.



Ambrx Biopharma PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Ambrx Biopharma's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=9.70/0.139
=69.78

Ambrx Biopharma's Share Price of today is $9.70.
Ambrx Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.14.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Ambrx Biopharma  (NAS:AMAM) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Ambrx Biopharma PS Ratio Related Terms

Thank you for viewing the detailed overview of Ambrx Biopharma's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ambrx Biopharma (Ambrx Biopharma) Business Description

Traded in Other Exchanges
Address
10975 North Torrey Pines Road, La Jolla, CA, USA, 92037
Ambrx Biopharma Inc is a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform that allows incorporating synthetic amino acids (SAAs) into proteins within living cells. Its product pipeline includes ARX788, ARX517, ARX305 among others.
Executives
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Margaret Dalesandro director ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Sonja Nelson officer: Chief Financial Officer C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BOULEVARD, 3RD FLOOR, FT. LAUDERDALE FL 33301
Daniel J. O'connor director, officer: President and CEO C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Abhishek Trehan 10 percent owner WHITELEY CHAMBERS, DON STREET, ST. HELIER Y9 JE2 4TR
Darwin Global Master Fund, Ltd. 10 percent owner C/O OGIER GLOBAL (CAYMAN) LIMITED, 89 NEXUS WAY, CAMANA BAY, GRAND CAYMAN E9 KY1-9009
Paul V Maier director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Janet Loesberg director C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Kate Hermans director C/O AMBRX BIOPHARMA INC., 10975 TORREY PINES ROAD, LA JOLLA CA 92037
Xiaowei Chang director 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Stephen C. Glover director 108 DOCKSIDE CIRCLE, WESTON FL 33327
Andrew Aromando officer: Chief Operating Officer C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Cormorant Private Healthcare Fund Iii Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen 10 percent owner C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116